Usage Examples
- The CMC section is holding up the filing; stability has two more months to run.
- FDA sent an information request on the CMC side asking us to justify the dissolution acceptance criteria.
- That site change is a major CMC change, so it needs a supplement before we ship anything made there.
What is CMC (Chemistry, Manufacturing, and Controls)?
CMC is the quality section of a drug application, covering the composition, manufacturing process, and controls for drug substance and drug product, as opposed to the nonclinical and clinical sections that establish safety and efficacy.
CMC exists because a clinical trial studies a handful of batches while the market receives thousands. An approval licenses a manufacturing process, not a molecule in the abstract. CMC is where the applicant demonstrates that the material given to trial subjects and the material shipped for the next decade are the same product, made the same way, held inside the same limits.
CMC covers the drug substance and the drug product: method of synthesis or isolation, physical and chemical characteristics, process controls, component lists, specifications, analytical procedures, container closure systems, stability data with proposed expiration dating, and each manufacturer's name and address. CMC stops where safety and efficacy begin. Whether the drug works, and at what dose, belongs to the nonclinical and clinical sections of the application.
CMC is applied on a sliding scale across the lifecycle. In an IND the expected depth varies with the phase, duration, dosage form, and information otherwise available, with initial Phase 1 emphasis on raw materials and the new drug substance. By NDA the process is locked and fully specified. After approval CMC becomes change control, and the size of the change decides the filing.
Not to be confused with
- GMP
- GMP governs how a facility actually operates and is enforced by inspection. CMC is the filed description of the product and process that a reviewer assesses on paper. A site can pass a GMP inspection and still have its CMC section rejected as incomplete.
- Module 3
- Module 3 is the location in the CTD where CMC content is filed. CMC is the content and the discipline. Saying "Module 3 is done" describes a document assembly state, not whether the underlying data supports the specifications.
- Prior Approval Supplement
- a PAS is the regulatory vehicle used to file a CMC change after approval, not the CMC information itself. 21 CFR 314.70(b)(1) is what decides whether a given change needs one.
- Process validation
- process validation is one body of evidence inside CMC, proving the commercial process performs reproducibly. CMC is the broader package: substance characterization, specifications, methods, stability, packaging, and facilities.
The obligations attach at filing and again at every change to what was filed.
What you must do
- 1Describe the composition, manufacture, and control of the drug substance and drug product in the IND, at a depth scaled to the phase, proposed duration, dosage form, and information otherwise available21 CFR 312.23(a)(7)(i)
- 2Provide a full description of the drug substance in the NDA, including physical and chemical characteristics, stability, manufacturer name and address, method of synthesis or isolation and purification, process controls, and the specifications ensuring identity, strength, quality, and purity21 CFR 314.50(d)(1)(i)
- 3List all components used in manufacture regardless of whether they appear in the finished product, with the composition statement, in-process controls, acceptance criteria covering sterility and dissolution rate, container closure systems, and stability data with proposed expiration dating21 CFR 314.50(d)(1)(ii)(a)
- 4Include in the NDA either a claim for categorical exclusion or an environmental assessment21 CFR 314.50(d)(1)(iii)
- 5Submit a supplement for any change in the drug substance, drug product, production process, quality controls, equipment, or facilities with substantial potential to adversely affect identity, strength, quality, purity, or potency21 CFR 314.70(b)(1)
Common mistakes
Carrying Phase 1 CMC habits into the NDA
early development legitimately emphasizes identification and control of raw materials and the drug substance, because 21 CFR 312.23(a)(7)(i) scales expectations to the phase. An NDA does not scale. Missing acceptance criteria, unvalidated methods, or short stability datasets convert into information requests that add review cycles to a filing that is otherwise ready.
Treating a manufacturing change as an internal quality decision
a new supplier, a new site, or a tightened process parameter is assessed by the applicant against 21 CFR 314.70(b)(1), not by the plant. A change with substantial potential to adversely affect identity, strength, quality, purity, or potency needs a supplement, and distributing product made under it beforehand is a compliance event, not a paperwork lapse.
Forgetting the environmental claim
21 CFR 314.50(d)(1)(iii) sits inside the CMC section and requires either a categorical exclusion claim or an environmental assessment. It is a single short document that teams routinely leave out because it feels unrelated to quality, and its absence is a filing deficiency on an otherwise complete dossier.
When This Matters
- The CMC section is holding up the filing; stability has two more months to run.
- FDA sent an information request on the CMC side asking us to justify the dissolution acceptance criteria.
- That site change is a major CMC change, so it needs a supplement before we ship anything made there.
Frequently Asked Questions
CMC stands for Chemistry, Manufacturing, and Controls. It is the quality section of a drug application, describing the composition, manufacturing process, specifications, analytical procedures, and stability of both the drug substance and the finished drug product. In CTD-format submissions this content is filed as Module 3, the Quality module.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
